At present, evaluation of serum prostate specific antigen (PSA) is part of the standard diagnostic work‐up in symptomatic cases3 but less suitable for prostate cancer screening in asymptomatic males due to low specificity4 and significant risk of false positivity5 which leads to overdiagnosis and overtreatment.6 This evidence concerns the gene KLK3 and Familial prostate cancer.